All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
Bookmark this article
The MDS Hub was pleased to speak to Uwe Platzbecker, University of Leipzig Medical Center, Leipzig, DE, during the Society of Hematologic Oncology (SOHO) 2023 Annual Meeting. We asked, “What do data from the phase III COMMANDS trial reveal about luspatercept as a treatment option?”
What do data from the phase III COMMANDS trial reveal about luspatercept as a treatment option?
Platzbecker discusses the open-label, randomized, controlled, phase III COMMANDS trial (NCT03682536), previously covered by the MDS Hub, which investigated luspatercept versus epoetin alfa for the treatment of anemia in transfusion-dependent, erythropoiesis-stimulating agent (ESA)-naïve patients with lower-risk myelodysplastic syndromes (MDS). He highlights the association of treatment with luspatercept and improved transfusion independence found in the trial, and discusses the impact of these results on clinical practice.
Luspatercept granted FDA approval as a first-line treatment for anemia in patients with lower-risk MDS
On August 28, luspatercept-aamt, a first-in-class erythroid-maturation agent, was approved by the FDA for the treatment of anemia in ESA-naïve,...
Luspatercept for ESA-naïve TD patients with LR-MDS: Interim analysis from the COMMANDS study
Here, we summarize an interim analysis from the COMMANDS trial recently published by Platzbecker, et al. in The Lancet, as well as presentations by Guillermo...
Luspatercept granted priority review by the FDA and type II variation application validated by the EMA for first-line treatment of anemia in lower-risk MDS
On May 1, 2023, the FDA accepted a supplemental biologics license application for...
Luspatercept approved for transfusion-dependent anemia in patients with MDS
Luspatercept: first-in-class erythroid maturation agent approved by the FDA and EMA for MDS.
Subscribe to get the best content related to MDS delivered to your inbox